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ABSTRACT 
KRISTEN J. KOLTUN:  The Effect of Estradiol on IL-6 Concentration in Response to an Acute Bout 
of Exercise 
(Under the direction of Anthony C. Hackney, Ph.D., D.Sc.) 
 This study attempted to find the effect of differing estradiol (E2) concentrations on the IL-6 
response to an acute bout of exercise.  Ten eumenorrheic women (n=10) who were not using oral 
contraceptives completed two 60 minute running sessions at 61% VO2 peak, once during the 
follicular phase (low E2) and once during the luteal phase (high E2) of the menstrual cycle.  Resting, 
immediately post exercise, and 30 minute recovery blood samples were assessed for IL-6.  Resting E2 
concentrations confirmed the appropriate hormonal status for each experimental session.  Neither the 
absolute concentration of IL-6 nor the percent change in IL-6 from rest was significantly different 
between phases (main effect and interaction effect; responses approached significance; p=0.07).  In 
conclusion, there is no relationship between E2 and IL-6 in response to exercise; although IL-6 trends 
towards being lower with high E2 concentration.  Based on this, it cannot be suggested that female 
athletes should alter training levels based on hormonal status, however, additional research is 
necessary as this study was underpowered (β=0.73). 
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CHAPTER I 
Introduction 
 The inflammatory response is a localized tissue response to injury,
1
 which consists of a series 
of non-specific events.
2,3
  This local response to infection or injury involves the production of 
cytokines, which are released at the site of inflammation.  Cytokines then act as intracellular signals, 
facilitating the arrival of other immune cells, such as lymphocytes, neutrophils, and monocytes, which 
work to clear any antigens and facilitate the healing process.
3,4
 
 Cytokines are released in two phases.  Those released early in the process include Tumor 
Necrosis Factor-alpha (TNF-α) and Interleukin-1 (IL-1).  These are pro-inflammatory cytokines 
which initiate and progress the inflammatory response.
3
  The second phase of cytokine release 
consists primarily of Interleukin-10 (IL-10) and Interleukin-1 Receptor Antagonist (IL-1ra), which 
are anti-inflammatory and lessen inflammation.
3
  Interleukin-6 (IL-6), which is released throughout 
the inflammatory response is an interesting cytokine because it is produced in larger amounts than 
any other cytokine and, at different points in the inflammation response, IL-6 may have different 
functions.  Early in the inflammatory response, IL-6 concentration is correlated with TNF-α and IL-1 
and acts as a pro-inflammatory cytokine.
18
  However, later in the response, IL-6 can upregulate IL-1ra 
and function as an anti-inflammatory cytokine.
2
   
Exercise has successfully been shown to result in local inflammation.  Numerous studies have 
demonstrated that IL-6 values increase in response to physical activity.
2-8
   Estrogen concentrations 
are also raised in response to acute exercise bouts.
5, 9-11
  Figure 1 demonstrates the timeline and 
interaction of the pro- and anti-inflammatory cytokines.
 2 
 
Figure 1.  The cytokine response during inflammation.  TNF-α and IL-1 are pro-inflammatory 
cytokines released early in the cascade.  Later, the anti-inflammatory cytokines are released. These 
include IL-10 and IL-1ra.
3
  IL-6 peaks immediately post-exercise and has both pro- and anti-
inflammatory effects.
2,18
  
 
Pedersen, 2000 
Figure 2.  Estrogen levels are low early in the cycle during the follicular phase, but rise just prior to 
ovulation.  They then decline and plateau during the luteal phase at a higher concentration than during 
menses.  At the end of the luteal phase, levels decline until menses begins.
1
 
 
 
Adapted from Tortora G.J. & Derrickson, B., 2009 
 
 3 
Estrogens are the end product of the hypothalamus-pituitary-gonadal axis.
12
  Estrogen levels 
fluctuate in a regular pattern across the menstrual cycle, with most cycles ranging from 24-36 days 
and lasting 28 days on average.  The follicular phase is the time prior to ovulation, which occurs at 
day 14, and the luteal phase is the second half of the cycle.  The mid-follicular phase is characterized 
by low estrogen levels, and the mid-luteal has higher estrogen levels.  Figure two demonstrates the 
cyclical pattern of estrogens during the menstrual cycle 
The three estrogens that circulate in females are estradiol, estrone, and estriol.  The most 
prevalent and biologically active of these is estradiol.
1
  Estrogens have many functions in the body, 
including a link to the inflammatory response.  Previous research suggests that estrogen, particularly 
estradiol, may have immune effects and be able to alter the inflammatory response, acting in an anti-
inflammatory capacity.
13, 14
 
Due to the immune and potentially anti-inflammatory effects of estrogen, the interaction 
between estrogen and IL-6 has been studied.  In vitro and murine studies have consistently shown that 
estrogen inhibits IL-6 production and the inflammatory response.
13, 15, 16
  Puder et al.
14
  demonstrated 
that estrogen supplementation attenuates the IL-6 response in post-menopausal women.  In studies 
conducted in humans in response to exercise, there has been conflicting data.  Estradiol 
supplementation in men did not result in a decreased IL-6 response after exercise, but it is thought 
that there are differences in the estrogen receptor or the inflammation pathway between the genders or 
that the exposure time to estradiol was insufficient
8
.  Timmons et al.
17
 conducted a similar study, 
involving eleven men, six women on oral contraceptives, and six women not using oral 
contraceptives.  This experiment found no significant differences in post-exercise IL-6 levels between 
the groups.  However, although there were no significant differences, the IL-6 concentration was 
greater in each group when estradiol was at a lower concentration.
17
  It is possible that the sample size 
for this study was not large enough to find any significance between groups.  Most recently Ives et 
al.
5
 found no significant differences in post-exercise IL-6 values across the menstrual cycle.  But, 
 4 
 
these women were on oral contraceptives and there were no significant differences in estrogen 
concentration across the two sessions.  Oral contraception minimizes the fluctuation in estrogen 
concentration across the menstrual cycle, which would limit the effects on IL-6.  Also, if the resting 
estrogen concentration was not significantly different between the two experimental trials and the 
exercise bouts were the same duration and intensity, it would not be expected that the change in IL-6 
concentration would differ between the trials.  Based on these results, there is mixed information on 
whether estrogen has an effect on IL-6.  There is a need for a study examining the effect of an acute 
bout of exercise on local IL-6 concentration in women not using oral contraceptives at points during 
the menstrual cycle when the estrogen concentration is significantly different.   
Statement of the Problem 
 The purpose of this experiment was to determine the effect of estradiol concentration on IL-6 
concentration in response to an acute bout of exercise in females who are not using oral 
contraceptives. 
Research Questions 
1. What is the acute effect of exercise on plasma IL-6 concentration? 
2. What is the effect of exercise and 30 minutes of recovery on plasma IL-6 concentration? 
3. Is there a significant difference in plasma estradiol values at rest between the follicular and luteal 
phases? 
4. Is there a significantly different %Δ in IL-6 concentration from rest to immediately post-exercise 
between the follicular and luteal phases? 
5. Is there a significantly different %Δ in IL-6 concentration from rest to 30 minutes of recovery 
between the follicular and luteal phases?
 5 
 
Research Hypotheses 
Hypothesis 1: Plasma IL-6 concentration will be significantly increased from rest immediately post-
exercise. 
Hypothesis 2:  Plasma IL-6 concentration will be significantly increased from rest after 30 minutes of 
recovery from exercise. 
Hypothesis 3: Pre-exercise plasma estradiol will be significantly higher during the luteal trials 
compared to follicular trials. 
Hypothesis 4:  The %Δ in plasma IL-6 concentration will be significantly lower during luteal trials 
compared to follicular trials from rest to immediately post-exercise. 
Hypothesis 5:  The %Δ in plasma IL-6 concentration will be significantly lower during luteal trials 
compared to follicular trials from rest to 30 minutes of recovery. 
Definition of Terms 
Inflammation – Acute inflammation is an early post-injury response characterized by a rapid increase 
in local blood flow and vascular permeability, and an influx of lymphocytes, such as neutrophils, and 
cytokines.
4 
Cytokines – Intracellular signals that are released at the site of inflammation and attract immune 
cells.
4
   
Pro-inflammatory Cytokine – These are cytokines that enhance the inflammatory immune response, 
such as TNF-α and IL-1.18 
Anti-inflammatory Cytokine – These are cytokines that restrict the magnitude and duration of the 
inflammatory response, and include IL-1ra and IL-10.
18
 6 
 
Interleukin-6 (IL-6) – This cytokine is released in large amounts in response to exercise and has both 
pro- and anti-inflammatory effects.
18
  IL-6 peaks immediately post-exercise and is primarily pro-
inflammatory at this time.
3 
Estradiol – The primary and most biologically active estrogen, which has a specific biological rhythm 
based on the menstrual cycle.
5
  It is believed to have a strong anti-inflammatory effect.
8 
Eumenorrhea – Having a regular menstrual period for at least the previous six months. 
Follicular Phase – The first phase of the menstrual cycle, which lasts from menses until ovulation at 
approximately day 14.  Estrogen levels remain low during this phase until there is a peak just prior to 
ovulation.
1 
Luteal Phase – Lasts from ovulation until menses begins.  It is characterized by estrogen levels that 
plateau, approximately between days 20-25, at a higher concentration than the follicular phase.
1
 
Assumptions 
1. Subjects adhered to all diet and physical activity recommendations prior to the experimental trials. 
Limitations 
1. A pre-testing diet was recommended, but the subjects will be left to follow the guidelines on their 
own. 
Delimitations 
1. Only healthy, recreationally active, college aged, eumenorrheic females who are not on birth 
control were recruited for this study. 
2. Diet was monitored, but not strictly controlled. 
3. Sixty minutes of exercise at 65% VO2 peak was the exercise duration and intensity.
 7 
 
4. Menstrual cycle phase was determined by the forward counting method
21
 and confirmed with 
urinary ovulatory kits. 
Significance 
 This study attempted to determine the relationship between inflammation and the menstrual 
cycle, particularly how estradiol affects IL-6 levels in response to an acute bout of exercise.  
Inflammation produces local swelling and pain,
1 
which can be uncomfortable and hinder future 
activities.  If inflammation is more severe, characterized by higher IL-6 levels, at different times in 
the menstrual cycle it may be a recommendation to decrease training levels or supplement with an 
anti-inflammatory drug during that phase.  If inflammation can be controlled, this may allow for a 
high training load to be maintained, which could result in a higher performance capability.    
 
  
 
 
CHAPTER II 
Review of Literature 
Introduction 
 This review of literature covers a variety of topics.  First, the basic inflammatory response is 
discussed, with a particular focus on the release of cytokines.  Following that, the role of IL-6 and its 
response to exercise is examined.  Next, the fluctuation in estrogen resulting from the menstrual cycle 
is introduced.  Estrogen is then further reviewed with respect to its roles in the body as well as how it 
is affected by an acute bout of exercise. Lastly, the interaction between IL-6 and estrogen is reviewed.  
This last portion begins with in vitro studies, then animal models and moves toward human based 
models ending with how this relationship is affected by exercise. 
Cytokine Response 
 An acute bout of exercise can act as a physical stress on the body, often leading to 
inflammation.  The inflammatory response is a localized tissue response to injury.
1
  This response 
consists of a series of non-specific events and local inflammation can lead to the systemic acute phase 
response.
2,3
  The local response to infection or injury involves the production of cytokines, which are 
then released at the site of inflammation.  These cytokines act as intracellular signals, facilitating the 
arrival of other immune cells, such as lymphocytes, neutrophils, and monocytes, which work to clear 
any antigens and facilitate the healing process.
3,4
 
 In response to exercise, or any other inflammation inducing event, there is a well-documented 
cascade of cytokines.  Cytokines that are released early include TNF-α and IL-1.  They are referred to
9 
 
 as pro-inflammatory because if they are injected, most, if not all, of the acute phase response will be 
produced.
3
  IL-6 alone will not induce inflammation and can be classified as an inflammation 
responsive cytokine.
3
  IL-6 has both pro- and anti-inflammatory effects, but immediately post-
exercise its role is primarily pro-inflammatory and it is highly correlated with TNF-α and IL-1.18  IL-
1ra and IL-10 are released into recovery from exercise and are anti-inflammatory in nature.
3
  All of 
these cytokines work in conjunction with each other in order to balance the inflammatory response, 
thereby allowing for recovery and healing of the damaged tissue.   
IL-6 Response to Exercise 
 Numerous studies have been conducted in order to determine the relationship between IL-6 
and an acute exercise bout.  The exercise has ranged from a various types of aerobic exercise, to 
eccentric leg contractions, and a later purpose was to determine what type of mode and intensity is 
necessary to induce an IL-6 response to exercise.  
The earlier study conducted by Ostrowski et al.
2
 had sixteen males complete the Copenhagen 
marathon.  Blood was drawn one week prior to the race, immediately post-exercise, and two hours 
post-exercise and was used to measure plasma IL-6 and the mRNA for IL-6.  Plasma IL-6 increased 
from 1.5 ± 0.7 pg/mL to 94.4 ± 12.6 pg/mL immediately after the race.  This study also found that 
mRNA for IL-6 was detectable after the marathon.  Ostrowski et al.
3
 followed up these findings with 
a similar study.  Similar testing was conducted on ten male runners in the next year’s Copenhagen 
marathon.  This study found similar results to the previous one and reported that IL-6 peaked 
immediately post-exercise, where it presented a 128 fold increase compared to pre-race values.  
 Later studies also used aerobic exercise to measure the IL-6 response to exercise, however 
they were conducted in a laboratory setting with a different duration and intensity.  Timmons et al.
8 
found a significant increase in IL-6 concentration after having eleven recreationally active men cycle 
for ninety minutes at 65% of their VO2 max.  Ives et al.
5
 required ten active females who used oral 
10 
 
contraceptives to run on a treadmill for one hour at 65% of their VO2 max and also found a significant 
increase above baseline values.   This shows that IL-6 will increase with sufficient exercise in both 
genders.   
 Other studies utilized resistance exercise as the stimulus for increased IL-6.  One particular 
protocol significantly increased IL-6 in twelve males after completing 300 eccentric leg contractions.
4
  
Steensberg et al.
7
 required subjects do five hours of knee extensions at 40% maximal workload.  This 
study not only further confirms that IL-6 will increase in response to exercise, but it also helps to 
target the source.  Arterial plasma concentration of IL-6 increased from 0.74 ng/L at rest to 14.13 
ng/L after five hours of one-legged knee exercise.  By drawing blood from the femoral artery and 
vein, it was possible to measure the IL-6 produced by the active muscle.  During this exercise bout 
net skeletal muscle IL-6 production increased significantly and this demonstrates that IL-6 can be 
produced by working muscle.   
 Mendham et al.
6
 examined the effect of mode and intensity of exercise on the acute IL-6 
response.  Four different exercise protocols were used.  Two were resistance exercises at either 60% 
or 80% of their 1 repetition maximum (RM).  The other two involved cycling at either 30% or 50% of 
their maximal aerobic workload.  All four protocols lasted 40 minutes to control for time.  When 
examining mode, there were no significant differences between the moderate-vigorous intensity 
exercise protocols.  The other main result from this study was that the acute increase in IL-6 was 
significantly larger in both moderate-vigorous intensity protocols compared to the low-intensity 
protocols.  In response to moderate-vigorous aerobic exercise the relative increase in IL-6 was 70.9  ± 
4.5 %.  Overall, this study suggests that when matched for time, moderate-vigorous resistance 
exercise and aerobic activities will result in similar IL-6 increases post-exercise.  All of these studies 
support the concept that IL-6 is significantly increased from baseline values after an acute bout of 
exercise in both men and women.  Also, the magnitude of the rise in IL-6 can vary depending on the 
duration and intensity of exercise.
11 
 
Menstrual Cycle Phases 
The sex hormone levels in females of reproductive age fluctuate in a cyclical pattern across 
the menstrual cycle.  A typical cycle ranges from 24-36 days.  Menses occurs approximately the first 
five days of the cycle and ovulation around day 14.
12
  The early days of the menstrual cycle, prior to 
ovulation, are referred to as the follicular phase and the days after ovulation are the luteal phase.  By 
knowing where an individual is during the menstrual cycle it is possible to predict whether estrogen 
levels will be high or low.   
 Early in the follicular phase, estrogen levels are low until around day 8, when the levels begin 
to rise.
1
  The baseline estradiol concentration during the follicular phase is 97.3 ± 19.0 pg/mL.
11
  
Estrogen levels peak at about day 12, just prior to ovulation.  After ovulation estrogen levels decline, 
but reach a plateau that is of a higher concentration than during the follicular phase at approximately 
days 20-25.
1
  During the luteal phase, baseline estradiol levels are 196.3 ± 20.0 pg/mL.
11
  After that, 
estrogen levels are lowered even further until menses when the cycle begins again.
1
 
Estrogens and Estradiol 
Estrogens are the end product of the hypothalamus-pituitary-gonadal axis.  Gonadotropin 
releasing hormone (GnRH) is released from the hypothalamus, which then stimulates the release of 
Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) from the anterior pituitary.  
These hormones affect the follicles, which then alter the estrogen levels.
12
   
 There are three estrogens that circulate in females.  These include estradiol (17β-estradiol), 
estrone, and estriol.  The most abundant of these and the one that has the largest effects on target 
tissues is estradiol.
1
  These estrogens have multiple functions throughout the body, which include 
stimulating bone and muscle growth, forming secondary sex characteristics, altering central nervous 
system activity, and maintaining the function of reproductive glands and organs as well as altering the 
endometrium.
1
12 
 
 What makes estrogen so relevant to the inflammatory process is that some research has 
indicated that this hormone, particularly estradiol, may have immune and anti-inflammatory effects.  
Physiological levels of estradiol have been observed to boost the immune response in young adults 
during the reproductive years.
13
  Similarly, cytokines can activate the hypothalamic-pituitary-adrenal 
axis and gonadal steroids can also affect this pathway, thereby altering the response to inflammatory 
stimuli.
14
  These findings suggest that estrogen may have a significant effect on the inflammatory 
pathway and this interaction should be studied further. 
Estrogen Response to Exercise 
 Previous studies have been conducted in order to examine the effect of exercise on estrogen 
and estradiol.  These experiments first sought to find if estrogen levels would be altered in response to 
the physical stress of exercise.  A later aim was to determine what type of stimulus would be 
necessary to induce those changes as well as examining phase differences. 
 Jurkowski et al.
11
  studied the effect of exercise on ovarian and gonadotropic hormones, as 
well as the effect of intensity and menstrual phase on these hormones.  The design of this study 
required nine healthy females with regular menstrual cycles, who were not on oral contraceptives, to 
exercise at two different time points during the menstrual cycle.  These time points were in the 
follicular (six to nine days after menses), and in the luteal (six to nine days after ovulation) phases.  
The exercise bout consisted of twenty minutes of cycling at 30-35% of their max power output, 
twenty minutes at 60-66% and then to exhaustion at 85-95% of maximal power output.  This study 
determined that estradiol will increase with exercise.  When comparing changes in concentration 
between the two testing dates, estradiol was only significantly higher at exhaustion during the 
follicular phase, but during the luteal phase estradiol increased with each rise in intensity.  When 
examining the effects of intensity, this study suggests that estradiol will increase with greater intensity 
13 
 
exercise.  Light exercise did not significantly increase estradiol levels from rest, but it was 
significantly higher in both the heavy and exhaustive exercise. 
 Bonen et al.
9
 further investigated the effects of an acute bout of exercise on the concentration 
of estradiol as well as on LH, FSH, and progesterone.  This study consisted of ten healthy females 
participating in thirty minutes of intense cycling with a mean intensity of 75% VO2 max.  Based on 
records of their menstrual histories their phase was determined.  These participants were mostly in the 
luteal phase and during menses, but some had cycles that were too irregular to determine.  Estradiol 
was measured pre- and post-exercise and the percent change was calculated.  Overall, estradiol 
increased from 163.3 ± 45.7 pg/mL pre-exercise to 185.7 ± 50.5 pg/mL post-exercise for a percent 
change of 13.5 ± 7.5%.  This study also suggests that there is relationship between the rise in estradiol 
and both the intensity and duration of exercise.  With respect to intensity, estradiol concentrations 
increased when exercise was at intensity greater than 60% VO2 max.  Duration of thirty minutes was 
a long enough stimulus to bring about these changes as well. 
 More recent research has been conducted, showing similar rises in estradiol in response to 
acute bouts of exercise.  Forty minutes of cycling at 75% of maximal heart rate has produced a 
significantly greater change in estradiol compared to control.
10
  One hour of treadmill exercise at 65% 
of VO2 peak has also caused increases in estradiol concentration.  Estradiol increased significantly 
with exercise, and there was no difference in concentration between thirty minutes and sixty minutes.
5
  
These studies add more evidence to the concept that estradiol concentrations will increase in response 
to an acute bout of exercise.  
Interaction of IL-6 and Estrogen 
Many studies have been conducted in order to determine the effects of estrogen on the 
inflammatory response, particularly on IL-6 levels.  These experiments have used in vitro cell 
14 
 
cultures, animal models, and human models and many different types of stress were utilized to induce 
inflammation. 
 One of the first studies on this topic used IL-1 and TNF-α to induce IL-6 production in 
human bone derived cells, as well as rat and murine osteoblasts.  Girasole et al.
15
 measured the 
inhibition of estradiol on IL-6 production.  In this study, under basal conditions, cells produced very 
little IL-6.  Cells treated with IL-1 and TNF-α had much higher levels of IL-6 demonstrating that 
these are effective ways of inducing an IL-6 response.  The addition of estradiol to these cells did not 
affect the basal production of IL-6 but it did significantly inhibit IL-6 when it was produced in 
response to either IL-1, TNF-α, or both.  Inhibition was in a dose-dependent fashion.  This study 
further examined if the inhibitory effect of estradiol on IL-6 was at the level of mRNA.  It was 
determined that pretreatment with estradiol caused a 49% decrease in IL-6 mRNA after exposure to 
both IL-1 and TNF-α.  These findings suggest that estrogens, such as estradiol, can have an inhibitory 
effect on IL-6. 
 Pottraz et al.
16
 examined the molecular basis of how estradiol inhibits IL-6 production using a 
human cell model (HeLa) as well as a mouse cell line (MBA 13.2).  These cells were treated with 
17α-estradiol, 17β-estradiol, progesterone, testosterone and diethylstilbestrol (DES; synthetic 
estrogen).  Some cells were transfected with an estrogen receptor plasmid and some were given a 
control.  In human HeLa cells that were both pretreated with17β-estradiol and had the estrogen 
receptor, the stressor of phorbol 12-myristate 13-acetate (PMA) did not stimulate the promoter region.  
The mean value of the reporting factor in cells given both the IL-6 plasmid and the estrogen receptor 
plasmid and which were treated with estradiol was significantly less compared to cells treated with 
only estradiol or those without the receptor.  In murine bone marrow cells that were treated similarly, 
cytokine stimulated production of IL-6 was also inhibited by estradiol.  Overall, this study observed 
that IL-6 production by bone marrow and bone-derived cells from rodents and humans is inhibited by 
15 
 
estradiol.  The hormone requires an estrogen receptor to be present in order to have an effect and the 
inhibition of IL-6 production by estradiol is through a receptor-mediated action. 
 Rather than just using a particular human or mouse cell line, mice as a whole have also been 
used as a model to study the interaction between estradiol and IL-6.  Kovacs et al.
13
 used 
burning/scalding of mice as a physical stress.  Young mice that were injured showed a larger increase 
in IL-6 levels compared to animals that were not burned.   Part of this study required the mice to be 
pretreated with estrogen.  In the injured mouse group, estrogen attenuated IL-6 production.  In the 
presence of estrogen, IL-6 levels were lowered to nearly half of the value compared to when they 
were injured but not treated with estrogen.   The IL-6 value in mice that were injured and treated with 
estrogen was not significantly greater than the value in mice that were not injured.  This experiment 
used a mouse model and burning as a stressor to induce an IL-6 response and it further demonstrates 
that treatment with estrogen can lower the IL-6 response. 
 On a larger scale, IL-6 and estradiol were examined in humans.  Puder et al.
14
 used an 
endotoxin to stimulate IL-6 production.  Endotoxin is known to stimulate the synthesis and release of 
inflammatory cytokines from peripheral monocytes and macrophages.  This study consisted of six 
females between the ages of 42-68 who were menopausal or had undergone an oophorectomy.  All of 
these women had low estrogen levels and they were treated with a transdermal estradiol patch for one 
month and injected with endotoxin.  Endotoxin successfully increased IL-6 concentrations in both the 
presence and absence of estradiol.  However, in the estradiol treated group, mean IL-6 values peaked 
at 341 ± 94 pg/mL compared with 936 ± 620 pg/mL in the control.  The area under the curve (AUC) 
of this response was also calculated.  The AUC for IL-6 calculated for a five hour period after 
endotoxin injection was 31.3% lower in the group treated with estradiol compared to the untreated 
group.  Although the mechanism is still unclear, this is another example of how the IL-6 response was 
attenuated in the presence of estradiol.
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 More recent studies have focused on this interaction in response to exercise.  Timmons et al.
8
 
used eleven healthy, recreationally active men and had them cycle at 65% VO2 max for 90 minutes.  
Each group was treated with estradiol for eight days and was left untreated for eight days.  Both trials 
resulted in an increase in IL-6, however no effect of estradiol supplementation was found.  A 
potential reason for there being no differences between groups could be based on gender differences 
in the estrogen receptor or that eight days was not a sufficient exposure time. 
 Timmons et al.
17
 did further research on this topic.  This time the subjects consisted of twelve 
women, six of which were on oral contraceptives, and eleven men.  They underwent the same 
exercise protocol consisting of 90 minutes of cycling at 65% VO2 max.  Women were tested during 
the follicular (day 8 ± 3) and luteal (day 20 ± 2) phases.  Resting levels of IL-6 were not significantly 
different across any group or menstrual phase.  Estradiol concentrations were lower in oral 
contraceptive users compared to non-users, and they did not fluctuate significantly across the 
menstrual cycle.  The estradiol concentration in men was 134 ± 70 pmol/L.  Estradiol in non-
contraceptive users in the follicular phase was 195 ± 188 pmol/L and in the luteal phase was 361 ± 
263 pmol/L.  In oral contraceptive users, estradiol was 42 ± 41 pmol/L in the follicular phase and 14 
± 11 in the luteal phase.  Post exercise IL-6 values were also different, but not significantly.  Men had 
a post exercise IL-6 concentration of 6.7 ± 2.8 pg/mL.  Non oral contraceptive users in the follicular 
phase had values of 7.7 ± 2.4 pg/mL and in the luteal phase had values of 6.3 ± 0.8 pg/mL.  Oral 
contraceptive users in the follicular phase had concentrations of 5.5 ± 2.1 pg/mL and in the luteal 
phase it was 6.8 ± 1.0 pg/mL.  Although there were no significant differences, the IL-6 concentration 
was greater in each group when estradiol was at a lower concentration.   
 Most recently, Ives et al.
5
 studied ten women on oral contraceptives and required them to run 
on a treadmill for one hour at 65% VO2 max.  This study also suggests that estradiol and IL-6 were 
not significantly related across phase or time.  However, in this study there were no significant 
differences in the estradiol concentration of the subjects across the two time points.
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 Many studies have examined the interaction between IL-6 and estrogen, particularly estradiol, 
in response to a physical stress.  Early in vitro and murine studies have suggested that there is a 
relationship between these two variables, and that estradiol will attenuate the IL-6 response.  Some 
human based studies have also supported this finding.  More recent experiments have used exercise as 
the stressor and measured estradiol and IL-6 values.  In these examples, there has been no significant 
effect of estradiol on IL-6 levels.    
Summary 
 This review of literature has provided information on numerous topics.  First, the basic 
inflammatory response to a stress was introduced.  Next, the IL-6 response to the physical stress of 
exercise was discussed.  Then, the fluctuations in hormone levels across the menstrual cycle were 
presented.  Next, the physiology of estrogen release was mentioned and how it relates to the immune 
response was introduced.  After that, the estrogen response to exercise was discussed.  Finally, the 
interaction between IL-6 and estrogen was detailed. 
 
 
  
 
CHAPTER III 
Methodology 
 This study consisted of three visitations for each participant.  The first session included an 
orientation and maximal oxygen uptake (VO2 max) test.  The next two sessions were the testing days, 
which occurred during the midfollicular and midluteal phases of the menstrual cycle.  During the 
orientation session the protocols were explained, participant characteristics were obtained, menstrual 
history was recorded, and VO2 max was measured.  Sessions I and II were the experimental tests 
which required participants to perform 60 minutes of treadmill running at 65% of their predetermined 
VO2 max.  Baseline, immediately post-exercise, and 30 minutes into recovery blood samples were 
taken to measure estradiol and IL-6 concentrations.   
Participants 
 Ten healthy, recreationally active, pre-menopausal women were recruited for this study.  
Sample size was estimated from previous research in this laboratory to have sufficient power based 
on ten subjects.  To be included in this study, participants had to be eumenorrheic for the past six 
months and have not used oral contraceptives or any other hormone therapy in the six months prior to 
participation.   Also, subjects could not currently be taking any anti-inflammatory medications, such 
as ibuprofen, naproxen, or aspirin.  Each participant was informed of the experimental protocol and 
any risks and rewards.  They signed an informed consent form in order to participate.  All participants 
refrained from strenuous physical activity and were asked to eat a diet similar in calories and 
carbohydrates 24 hours prior to both of the experimental trials.
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Instrumentation
 Height was determined using a portable stadiometer (Perspectives Enterprises, Portage, MI).  
Body mass was measured using a mechanical scale (Detecto, Webb City, MO).  Skinfolds were 
measured with a Lange skin caliper (Beta Technology, Inc., Santa Cruz, CA).  Maximal oxygen 
consumption was determined during a continuous, incremental treadmill test on a Quinton Q65 
treadmill (Bothell, WA).  Respiratory gases were obtained for the orientation session, as well as the 
two experimental sessions using the Parvo Medics TrueMax 2400 Metabolic System (Parvo Medics, 
Salt Lake City, UT).  Heart rate was monitored continuously using the Polar telemetry system (Polar 
Electro, Inc., Lake Success, NY).  Ratings of perceived exertion were determined using Borg’s 20 
point scale.  Ovulation kits (Baby Hopes, Morrisville, NC) were used to determine menstrual cycle 
phase.  Hematocrit was determined using an Adams MHCT II microhematocrit centrifuge (Becton 
Dickinson, Franklin Lakes, NJ) and an International Microcapillary Reader (International Equipment 
Company, Needham Heights, MA).  Hemoglobin was determined from a Stanbio Lab Hemopoint H
2
 
analyzer (Boerne, TX).  Whole blood samples were placed in an IEC Centra-8R refrigerated 
centrifuge (International Equipment Company, Needham Heights, MA) and the resultant plasma was 
stored.  Plasma IL-6 was measured using BioLegend Legend Max
TM
 ELISA kits (San Diego, CA).  
Plasma estradiol was measured using the radioactive (
125
I)  immunoassay technique, (Siemens 
Healthcare Technologies, Los Angeles, CA).  Lactate was measuring using a NOVA Biomedical 
Lactate+ Analyzer (Waltham, MA). 
Protocol 
Pre-Screening 
 Potential subjects emailed and made contact with the investigator.  During that 
correspondence, it was determined if they fit all inclusion and exclusion criteria.  Upon being 
accepted to the study their orientation and experimental sessions were scheduled.
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Orientation Session 
 The participant arrived at the Applied Physiology Laboratory and was informed of the 
experimental protocol, made aware of possible risks and rewards associated with the protocol, and 
signed an informed consent form (Appendix A).  After consenting to participate in the experiment, 
the participant underwent a physical screening and a 12 lead electrocardiogram.  Once the participant 
filled out the medical history questionnaire (Appendix B) and passed the medical screening, physical 
characteristics including height, weight, and age were obtained.  Percent body fat was determined 
from skinfold thicknesses, gluteal circumference and age using the Jackson, Pollock and Ward 
method.
19
   
 Following this, VO2 max was determined using a continuous, incremental treadmill test.  The 
participant began with a short warm up of her preferred pace followed by some light stretching.  After 
the warm up, resting oxygen consumption (VO2) was recorded for three minutes.  The participant 
then began the graded exercise test.  A Bruce treadmill protocol was used.
20
  Figure 3 lists the three 
minute stages of the Bruce protocol treadmill test.  Heart rate (HR), rating of perceived exertion 
(RPE), and respiratory gases were monitored constantly throughout the test (Appendix E).  After the 
test was completed, the participant recovered actively or passively and was able to leave the 
laboratory once their heart rate returned to less than 100 beats per minute (bpm).  For the VO2 max 
test to be valid, a participant must have three of the following four criteria:  a plateau in VO2 with 
increases in workload, respiratory exchange ratio (RER) greater than or equal to 1.1, RPE > 18, and 
HR within 10% of predicted max HR.  Exercise intensity estimated to be 65% of VO2 max was 
calculated mathematically using ACSM guidelines.
20
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Figure 3.  The speed (mph; miles per hour) and grade for each three minute stage of the Bruce 
protocol incremental exercise test. 
Stage Speed  
 
(mph) 
Grade 
 
 (%) 
1 1.7 10 
2 2.5 12 
3 3.4 14 
4 4.2 16 
5 5.0 18 
6 5.5 20 
7 6.0 22 
 
Sessions I and II 
 Participants arrived at the Applied Physiology Laboratory at one point during the mid-
follicular phase of the menstrual cycle and at one point during the mid-luteal phase.  Menstrual cycle 
phase was determined and scheduled based on the forward counting method
21
 and confirmed by 
urinary ovulation kits (Appendix C).  The two experimental trials were counterbalanced to prevent 
any order effects.  The menstrual cycle is being used to manipulate the estrogen levels between the 
two trials.  Early in the menstrual cycle, during the mid-follicular phase (approximately between days 
3-7), estrogen levels are low.  Later in the cycle, during the mid-luteal phase (approximately days 20-
25), estrogen levels are significantly higher.  Based on this natural fluctuation, the effect of differing 
estrogen levels can be examined.  The two sessions were scheduled during these two phases in order 
to utilize the natural variation in estrogen concentrations; however, the exact days varied depending 
on the actual length of the subject’s menstrual cycle.  Twenty four hours prior to the experimental 
trials participants were told to refrain from strenuous physical activity and completed a food diary so 
that nutrient intake was relatively constant between the two trials.  Both experimental trials were done 
at similar times in the day in order to minimize any effects of circadian rhythms on hormone 
concentrations.
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 Participants were asked if they complied with all guidelines and their responses were 
recorded.  Dietary logs were collected to ensure that participants were consuming adequate calories 
and carbohydrates.  After compliance was given, participants rested in the supine position for ten 
minutes.  After ten minutes resting, blood was obtained (3 mL) using the standard venipuncture 
technique.  The blood sample was placed in a sterile K2-EDTA (purple top) Vacutainer
TM
 tube and 
immediately put on ice.  Next, participants completed five minutes of a warm up and stretching.  The 
participants then ran for 60 minutes at the previously determined workload of 65% of VO2 max 
(Appendix F).  Sixty minutes at 65% intensity was chosen in order to ensure that both estradiol and 
IL-6 would be elevated in response to the exercise.
6,9,18
  After completion of the 60 minutes of 
exercise, a blood sample (3 mL) was obtained and immediately put on ice.  A third and final blood 
sample draw (3 mL) was taken at 30 minutes into recovery.  Plasma was separated from blood 
samples and stored at -80° C until later analysis for estradiol, IL-6, and lactate. 
Blood Procedures 
Hematocrit 
 Resting and post-exercise Hematocrit (Hct) values for each of the experimental trials were 
determined in triplicate from whole blood samples immediately at the time of exercise tests.  Whole 
blood was drawn into 75 mm Allied Corporation microcapillary tubes (Fisher Scientific, Pittsburgh, 
PA) and sealed using Critoseal (Krackeler Scientific, Albany, NY).   Capillary tubes were then spun 
in a microhematocrit centrifuge for three minutes at 10,000 RPM.  The capillary tubes were then 
placed on a hematocrit wheel to determine the hematocrit values of each sample.  A mean of the three 
samples was calculated and used in data analysis.
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Hemoglobin 
 Resting, immediately post-exercise, and recovery hemoglobin (Hb) values were determined 
in duplicate from the whole blood samples of the experimental trials using the Stanbio Lab 
Hemopoint H
2
 analyzer (Boerne, TX) immediately at the time of exercise tests. 
  Plasma Volume Shift 
 Exercise induced plasma volume shifts were calculated from Hb and Hct values according to 
the Dill and Costill method.
22
  Plasma volume shift was used as a potential explanation for changes in 
cytokine and estradiol concentrations. 
Cytokine (IL-6), Estradiol and Lactate Assays 
 Whole blood was centrifuged at 3,000 x g for 10 minutes to separate the plasma.  The 
resultant plasma was transferred to storage tubes and stored at -80°C until cytokine and estradiol 
analyses were conducted.  Plasma estradiol was measured using the radioactive (
125
I) immunoassay 
technique (Siemens Healthcare Technologies, Los Angeles, CA) involving solid-phase antibody 
procedures.  The assay manufacturer reports a minimal detectable level of 2.0 pg/mL.  Plasma levels 
of IL-6 were measured using high-sensitivity enzyme-linked immunosorbent assay kits (BioLegend, 
San Diego, CA). The assay manufacturer reports a minimum detectable concentration of 1.6 pg/mL 
(Appendix D).  Lactate was measured using a NOVA Biomedical Lactate+ Analyzer (Waltham, MA) 
with a reported minimum-detectable concentration of 0.5 mM/L.  All blood assays (unknowns) were 
performed in duplicate while standards were in triplicate (For details, see Appendix).   
Data Analysis 
 All data were analyzed using SPSS statistical software (version 18.0, Chicago, IL).  
Significance was set at α<0.05.  Descriptive statistics are presented as means ± standard deviations 
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(SD).  In addition, effect size was calculated for all significant measures.  This later calculation was 
used to determine practical vs. significant findings. 
 A 2x3 (estradiol level x time) totally within subjects repeated measures ANOVA with a 
Bonferoni post-hoc test was used to evaluate the effects of estradiol on IL-6 concentration.  A 2x2 
(estradiol level vs. time) ANOVA was used to evaluate the percent change (%Δ) in IL-6 values 
between pre- and post-exercise and recovery during each menstrual cycle phase (estradiol level).  
Percent change was calculated using the equation: 
% Δ = [(Post-exercise-Baseline)/Baseline] x 100 
 Resting levels of estradiol at midfollicular and midluteal phase experimental sessions were 
statistically tested for differences using a dependent t-test analysis. 
  
  
CHAPTER IV 
Results 
Subject Characteristics 
Twelve active female subjects were recruited for this study.  Ten of the twelve subjects 
recruited fully completed all aspects of the study protocol.  Two subjects were forced to withdraw due 
to personal reasons.  All subjects recruited met the inclusion criteria of being eumennorheic and not 
using oral contraceptives for the previous six months.  Ovulation kits confirmed normal menstrual 
function for all subjects.  Participant physical characteristics are reported in Table 1. 
Table 1: Physical characteristics of the participants (n=10).  Values are Means (+ SD). 
Measure Mean + SD Range 
Age (yrs) 20 + 2 18-25 
Height (cm) 164.1 + 5.5 155.9-176.9 
Mass (kg) 58.7 + 7.9 43.1-68.5 
Body Fat (%) 20.0 + 5.9 11.1-28.5 
 
VO2 Peak Testing 
 Only eight of the ten participants who completed the study met the criteria for a valid VO2 
max test during the incremental exercise test (see Methods chapter).  Because of this, all maximal 
oxygen uptake results will be referred to as VO2 peak tests. 
 The absolute VO2 peak  (mean + SD) obtained was 2.96 + 0.57 L/min (range 2.00-4.04 
L/min) and the relative VO2 peak obtained was 50.4 + 8.2 mL/kg/min (range 38.4-64.6 mL/kg/min).  
The peak HR obtained was 195 + 9 bpm (range 184-209 bpm) and the peak RPE obtained was 18 + 1 
Borg units (range 15-20 Borg units).  The duration of the exercise test was 11.57 + 1.24 minutes 
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(range 9.49-13.15 minutes) ending with an average stage of 4.25 + .45 of the Bruce protocol (range 4-
5) corresponding to a speed of 11.4 + 1.0 km/h (range 10.9km/h-13.0 km/h)  and an incline of 17 + 
1% (range 16-18%).  These responses suggest the subjects were at a high level of cardiovascular 
fitness based upon the ACSM guidelines.
18
 
Hormonal Status Determination 
 Menstrual cycle length for the subjects who completed all aspects of the protocol (n=10) was 
30 + 3 days (range 25-35 days).  Individual menstrual cycle phases were estimated using the forward 
counting method
21
 and confirmed by urinary ovulation kits (see Methods chapter). The day on which 
subjects performed the running exercise during the midfollicular phase was 5 + 3 days (range 2-9 
days) after the onset of menses.  The day on which subjects performed the running exercise during the 
midluteal phase was 24 + 4 days (range 18-29 days) after the onset of menses. 
 Hormonal analysis of resting blood samples for estradiol confirmed the appropriate menstrual 
phase and hormonal condition of the subjects.  The midfollicular estradiol concentration was 27.04 + 
6.12 pg/mL and the midluteal estradiol concentration was 67.64 + 21.70 pg/ml.  The difference in 
estradiol concentration between the two phases was significantly different (p<.001). 
Extended Running Session 
 Each participant completed two sixty minute running trials, one of which was during the 
midfollicular phase of the menstrual cycle and the other after ovulation during the midluteal phase.  
All subjects complied with all pre-session guidelines (see Methods chapter) before each of the 60 
minute trials.  Each running trial was to consist of 60 minutes of running at 65% VO2 peak.  The 
overall mean absolute running VO2 was 1.81 + 0.46 L/min and the relative running VO2 was 31.2 + 
7.8 mL/kg/min.  This corresponded to an actual running intensity of 61.3 + 7% (range 49.9-73.1%) 
for both trials.
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 No significant difference in the relative running VO2 (p=.103) or absolute VO2 (p=.066) 
between the two phases was found.  Although there was no difference in VO2 across hormonal 
conditions, relative VO2 did demonstrate an increase in effort over time.  Analysis showed a higher 
VO2 at time points 30 and 60 minutes compared to minute 10 (p=.035, p=.016, respectively); i.e., 
main effect for time.  However, there was no significant difference in VO2 between 30 minutes and 
60 minutes (p=.187).  Also, no interaction effect was found between phase and time point for VO2. 
 No significant main effect for menstrual cycle phase or interaction effect was found for HR.  
However, ANOVA results did indicate a significant main effect for time during exercise (p<.001).  
Post Hoc analysis indicates that HR at all time points was significantly higher than rest (p<.001) and 
that HR was significantly higher at 60 minutes compared to 30 minutes (p=.049).  Mean HR was not 
significantly higher from minute 10 compared to minute 30 (p=.631) or minute 60 (p=.096). 
Similarly to HR, there was no significant main effect for menstrual cycle phase with regards 
to RPE (p=.111) although there was a significant main effect for time.  Post Hoc analysis indicates 
that at minute 30 and minute 60, RPE was significantly higher than at minute 10 (p=.019, p=.007, 
respectively) and RPE was also significantly higher at minute 60 compared to minute 30 (p=.005).  
Lactate immediately post-exercise was not significantly different between the two phases 
(p=.160).  The lactate concentration during the midfollicular phase was 2.95 + 1.80 mM/L.  During 
the midluteal phase it was 2.41 + 1.29 mM/L. 
Plasma volume increased by +0.7 + 23.8% over the sixty minute running bout during the 
midfollicular phase, whereas it decreased by -5.3 + 10.7% during the midluteal phase. These plasma 
volume shifts, however, were not significantly different between the hormonal conditions (p=.182).
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Table 2: Mean (+ SD) VO2, HR, and RPE for prolonged running bouts for the midfollicular and 
midluteal menstrual phases. 
Menstrual 
Cycle Phase 
Measure Time 
REST 10 min 30 min 60 min 
Midfollicular VO2 
(mL/kg/min) 
4.51 +  
0.65
*
 
30.73 + 
8.11
€
 
32.02 + 
7.78 
32.63 +  
8.08 
HR (bpm) 75 + 13
¥
 153 + 25 161 + 19 170 + 19 
RPE  10 + 2
√
 11 + 2
£
 13 + 3 
Midluteal VO2 
(mL/kg/min) 
4.89 +  
0.59
* 
29.74 + 
8.07
€
 
30.91 + 
8.02 
31.42 +  
7.95 
HR (bpm) 66 + 12
¥ 
155 + 18 164 + 18 167 + 19 
RPE  10 + 2
√
 12 + 3
£
 14 + 3 
A “   ” indicates no value was recorded for that particular time point.  * Indicates a significantly lower VO2 compared to 10, 
30 and 60 minutes (p<.001).  € Indicates a significantly lower VO2 compared to 30 and 60 minutes (p<.05).  ¥ Indicates a 
significantly lower HR compared to 10, 30, and 60 minutes (p<.001).  √ Indicates a significantly lower RPE compared to 30 
and 60 minutes (p<.05).  £ Indicates a significantly lower RPE compared to 60 minutes (p<.05). 
 
Cytokine (IL-6) Response to Running Trials 
Resting, post exercise, and recovery IL-6 concentrations as well as the percentage change 
from rest are reported in Table 3.  There was no significant main effect for phase (p=.076) or the 
interaction effect (p=.069) for the absolute concentration of IL-6.  The only significant finding for 
absolute IL-6 concentration was a main effect for time (p=.003).  Post Hoc analysis indicates that IL-
6 was not significantly elevated from rest to immediately post exercise (p=.072), but that IL-6 
concentration did increase significantly from rest to 30 minutes of recovery after exercise (p=.003).  
The effect size for this change was 0.963 (Cohen d) which is between a moderate (0.6 Cohen d) and 
large (1.2 Cohen d) effect.
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Since all IL-6 changes observed were substantially greater than the plasma volume shifts 
detected, no fluid shift corrections of IL-6 concentrations were conducted. 
The percent change of IL-6 from rest to immediately post-exercise and from rest to 30 
minutes of recovery was also examined.  The main effect for phase was not significant (p=.072).  
When comparing the relative change  from rest between immediately post-exercise and 30 minutes of 
recovery there was also no significant difference (p=.301)  and no significant interaction effect 
between phase and time was found either (p=.768). 
Table 3:  Mean (+ SD) IL-6 response and percent change (relative to rest) during the prolonged 
running bout for midfollicular and midluteal menstrual phase. 
Menstrual 
Cycle Phase 
Time 
 Rest 
(pg/mL) 
Immediately 
Post Exercise 
(pg/mL) 
Immediately 
Post Change 
(%) 
30 Minutes 
Recovery 
(pg/mL) 
Recovery 
Change 
 (%) 
Midfollicular 6.25 + 6.84 35.85 + 50.69 517.85 + 
415.16 
41.11 + 30.65 684.88 + 
318.24 
 
Midluteal 8.46 + 9.65 16.40 + 12.40 266.33 + 
348.56 
12.73 + 14.59 361.51 + 
928.89 
 
 
Estradiol-IL-6 Relationship 
 As an exploratory analysis, correlations (Pearson) were calculated between the difference in 
estradiol concentration between phases and the difference in IL-6 concentration between phases for 
the immediately post-exercise and the 30 minutes into recovery samples.  The correlation between 
estradiol and IL-6 immediately post was r=0.168 (p=.643) and the correlation between estradiol and 
IL-6 during recovery was r=0.108 (p=.766), neither of which were statistically significant.
  
CHAPTER V 
Discussion 
The purpose of this study was to determine the effect of estradiol fluctuations during the 
menstrual cycle on IL-6 concentration at rest and in response to an acute bout of exercise in females 
who are not using oral contraceptives.  It was hypothesized that the IL-6 concentration after exercise 
would be significantly lower during the midluteal phase of the menstrual cycle when estradiol 
concentrations are elevated.  This chapter will address this purpose and report on whether the study 
design was effective, describe the cytokine response to exercise and relate the findings to previously 
published literature, and explain possible reasons for these outcomes.   
 Study Design 
 Hormonal Condition 
 In order to use the natural fluctuation of estradiol in females, subjects were tested once during 
the midfollicular phase and once during the midluteal phase of the menstrual cycle.  That is, after the 
onset of menses, during the midfollicular phase, estradiol levels are low, whereas during the midluteal 
phase, estradiol levels plateau at a higher concentration.  All subjects were able to perform the 
prolonged running bout once during each phase.  Because of the cyclical nature of female hormone 
levels, having a subject tested during a particular menstrual phase it did not ensure that the estradiol 
levels would change and be significantly different.  For this study, however, statistical analysis 
confirmed that the estradiol concentration was significantly different between the two menstrual cycle 
phases and changed in the expected manner.  Estradiol concentration during the midluteal phase was 
more than double that of the midfollicular phase (67.64 + 21.70 vs. 27.04 + 6.12 pg/mL, 
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respectively), thus all subjects demonstrated the correct hormonal changes between the two testing 
sessions with midluteal estradiol concentration being higher than the midfollicular estradiol 
concentration.  These hormonal values fell within the physiologically accepted ranges for each phase 
and the fact that the estradiol concentration was approximately doubled from the midfollicular phase 
to the midluteal phase also agrees with numerous other studies.
9,11,23 
  However, the absolute 
concentrations of estradiol were lower than that found in some studies.
9,11,23,24
  Jurkowski et al.
11 
reported a midfollicular estradiol concentration of 103.8 + 16.0 pg/mL and a midluteal concentration 
of 199.5 + 16 pg/mL.  Bonen et al.
9
 had even higher values of 163.3 + 45.7 pg/mL for the 
midfollicular phase and 266.1 + 87.8 pg/mL for the midluteal phase.  The most similar numbers to the 
current were found by Fu et al.
31
 who reported follicular estradiol concentration as 34.1 + 12.3 pg/mL 
and luteal estradiol concentration as 55.3 + 20.4 pg/mL.  The somewhat lower absolute 
concentrations in the present study could be a result of the high physical activity levels of the current 
subjects.  That is, estrogen levels have been shown to decrease after aerobic training
30
 and all subjects 
in the present study were physically active individuals. 
Prolonged Running Bout 
 All participants successfully completed 60 minutes of treadmill running on the two separate 
occasions at an average intensity of 61% of VO2 peak.  This intensity is slightly lower than the goal of 
65% of VO2 peak intended, but research would suggest this is intense enough to illicit a rise in IL-6.
6
  
For all subjects, the speed and grade of the treadmill during each run was identical between the two 
trials.  In order to limit the effect of natural circadian rhythms the two trials for each individual were 
at approximately the same time of day.  However, the time of day for all trials was not consistent for 
all subjects.  Furthermore, due to time constraints of the study, participants were not evenly 
counterbalanced.  Seven subjects performed the midfollicular trial first while three subjects performed 
the midluteal trial first.  This potential order effect could lead to some degree of error in findings, 
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although there was no apparent differences in responses of the seven subjects tested in one order and 
the three tested in the opposite order.  Also, the performance characteristics of the exercise were not 
different between sessions.  
 No difference in VO2, HR, or RPE values was found between phases for the 60 minute 
exercise trials (main effect for phase).  This is consistent with other literature that has examined 
exercise performance across the menstrual cycle.
23,26,27
  The one study that did find a significant 
difference in RPE between menstrual cycle phases was conducted in a population of sedentary 
women.
28
  These less active subjects might experience a different level of exertion during exercise, as 
well as being less experienced in monitoring exercise exertion.  The non-significant difference in 
lactate concentration immediately after exercise also agrees with other studies that have examined this 
relationship.
23,25-27
  Collectively, the similar VO2, HR, RPE, and lactate data confirm the subjects’ 
exercise sessions were highly alike and suggest any IL-6 response differences were not due to 
differing aspects of the exercise sessions. 
In response to the 60 minute exercise, all values were elevated compared to the resting 
values.  Oxygen uptake increased at each time point and then plateaued from minute 30 until the end 
of exercise.   Thus, the second half of the exercise was at a steady state VO2.  Heart rate increased 
from rest and remained relatively level from 10 minutes to 30 minutes and then increased slightly at 
60 minutes.  Based on this rise in HR the end of the exercise session was more physiologically 
difficult compared to the beginning of the session.  Based on the HR response, exercise was not at a 
steady state for the entire 60 minutes of running.  An increase in HR towards the end of a long 
endurance exercise is, however, consistent with the cardiac drift phenomenon.
29
  During prolonged 
exercise plasma fluid can be lost from the blood, thereby reducing venous return and cardiac output.  
As cardiac output declines, HR must increase in order to maintain a given VO2.
29
  From minute 30 to 
minute 60 of exercise as the VO2 remained level, HR rose significantly. 
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Perceived exertion continued to rise at each measurement time point which demonstrates that 
the exercise became progressively more difficult during the 60 minutes, in agreement with the HR 
findings.  Although the exercise was at a constant intensity, RPE increased throughout the prolonged 
running bout which could be attributed to the extended length of the exercise bout and potential 
subject fatigue. 
Lactate concentration immediately post exercise was also not significantly different between 
the two sessions.  This is consistent with other studies that have measured this variable.
25-27
  These 
studies did not have the same exact exercise component (i.e., intensity, duration) but they all had the 
same findings that lactate was the same between phases at all time points and intensities.   Based on 
the extended duration of the exercise bout, and the subjects’ need to run below their lactate threshold 
(i.e., a moderate intensity), the observed lactate concentrations were similar to what was expected 
based on the literature.
25,27 
Cytokine Response 
 Exercise Effects 
 The average resting concentration of IL-6 for all twenty exercise sessions was 7.35 + 2.43 
pg/mL.  This resting concentration is higher than most other exercise study reports.  In male subjects 
Ostrowski et al.
2
 reported resting IL-6 concentration as 1.5 +0.7 pg/mL, while Steensberg et al.
7
 had 
resting concentrations of 0.74 (range, 0.67-1.50) pg/mL, and Mendham et al.
6
 measured IL-6 at 1.31 
+ 0.28 pg/mL.  In non-oral contraceptive using females pre-exercise IL-6 concentration was 2.0 
pg/mL as reported by Timmons et al.
8
  Chaffin et al.
24
 also had resting values less than 2.00 pg/mL, 
both of which are lower than the results of this study.  The finding of elevations in resting IL-6 in the 
present subjects could be a result of excessive background interference in the assay outcomes due to a 
limited practical experience by the investigator performing the assays; nonetheless, the levels were 
relatively similar across and within all the subjects.  This last point suggests there was good internal 
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validity in the data.  An additional factor accounting for the elevated resting IL-6 may be related to 
the study design pre-exercise protocol.  Holmes et al.
36
 report that the level of resting IL-6 is 
inversely related to the level of circulating free fatty acids (FFA).  At rest, the circulating level of 
FFA is directly related to the duration of a post-prandial fast.  The pre-exercise fast that the subjects 
were asked to complete was relatively short compared to most studies being only two hours.  This 
means the subjects started the exercise trials with low FFA levels, and thus elevated IL-6.  Holmes et 
al.
36
 reported resting IL-6 levels as 6.05 + 0.89 pg/mL for their subjects having FFA levels at that 
expected for the present study subjects based upon their level of fasting.  The IL-6 concentration of 
Holmes et al.
36
 match very similarly with that of the present study. 
 Interleukin-6 concentration increased from rest after the 60 minutes of running, but this 
change was not significant (p=.072; main effect time).  There was a concentration of 26.13 + 9.03 
pg/mL immediately after exercise.  This concentration continued to rise until 30 minutes of recovery 
from exercise where it was 26.92 + 5.54 pg/mL, this concentration is significantly elevated compared 
to rest (p<.05).  Most studies have found that IL-6 peaks immediately after exercise
2,3,6,18
.  However, 
there are various factors that can affect the cytokine response.  These include the type of physical 
activity, the type of contraction, as well as the intensity and duration of exercise.  The rise in IL-6 is 
most closely related to the duration of the exercise bout
18
.  The absolute IL-6 concentration after 
exercise in this study was higher than some previous studies
4,6,5,8,18
 but lower than others.
2,3,6
  The IL-
6 response to aerobic endurance exercise in men has been reported by Ostrowski et al.
2
 as reaching a 
level of 94.4 +12.6 pg/mL after completion of a marathon.  Timmons et al.
8
 found that IL-6 rose to 
approximately 7.0 pg/mL after cycling for 90 minutes at 65% of VO2.  There is far fewer data with 
respect to females who were not using oral contraceptives and underwent aerobic exercise.  One study 
found that IL-6 rose to approximately 7.0 pg/mL after 90 minutes of cycling at 65% VO2max.  The 
difference in IL-6 concentration between these studies could be attributed to the type of exercise that 
the subjects were required to complete and the subjects training background.  The non-significant 
 35  
immediate post-exercise value was not expected but the fact that the recovery values were 
significantly greater than rest suggests that the exercise bout intensity and duration was sufficient to 
illicit a rise in IL-6 (N.B., the slightly higher variable observed in the SD at the immediate versus 
recovery concentration most certainly affected the lack of detection of a significant increase).   
 The increase in IL-6 following exercise was about 3.5 fold for the current study.  Most other 
studies do not report the percent change from rest but the fold increase is able to be determined.  
While the marathon studies have reported that IL-6 rose as much as a 128-fold,
3
 the current findings 
are close to studies with similar aerobic exercise components.  In two studies Timmons et al.
8,17
 found 
that IL-6 had a 3-fold increase in concentration.  Ives et al.
5
 found about a 3.5 fold increase as well in 
oral contraceptive using females, while Chaffin et al.
24
 had approximately a 4-5 fold increase in non-
oral contraceptive using females. 
 Menstrual Phase Effects 
 The primary research question of this study was to examine the relationship between estradiol 
and IL-6 in active females who do not use oral contraceptives.  The results of this study suggest that 
there is no significant difference in IL-6 concentration in response to varying estradiol concentrations 
either at rest or in response to exercise.  When examining the interaction effect between phase and 
time there were no significant findings.  Although the IL-6 concentration was lower in the midluteal 
phase compared to the midfollicular phase at all time points, the difference was not large enough to 
be significant (p=.074; interaction effect).  With respect to percent change, this finding was also not 
significant (p=.072).  In both cases the effect nearly reached statistical significant and had there been 
less variability in the IL-6 response significance might have been reached based on the critical 
statistical criteria of 0.05.    
 In animal and in vitro studies, IL-6 concentration was consistently found to be lower in 
response to higher estrogen concentrations.  Studies conducted in mice determined that estradiol 
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treatment significantly decreased the production of IL-6 and that estrogen treated mice had an 
attenuated IL-6 response.  
13,16
  In human cells, in vitro estradiol treatment lead to a smaller rise in IL-
6 production as induced by other pro-inflammatory cytokines.
15
  An in vivo, human study has also 
found that IL-6 was attenuated by estrogen supplementation in healthy women who were exposed to 
endotoxin, which promotes pro-inflammatory cytokine responses.
14
  
 In response to exercise the results of some previous studies have not found that estrogen 
affects IL-6.  Two separate studies required subjects to cycle at 90 minutes at 65% VO2 max.  In one 
study, estrogen supplementation had no effect on the IL-6 response.
8
  The other study utilizing this 
exercise session reported that IL-6 levels were not different between menstrual cycle phase within 
female subject and that there was no difference in IL-6 responses between genders.
17
  Ives et al.
5
 
tested oral contraceptive using females and did not find a significant interaction between phase and 
time or main effect for time; although, the reported changes did approach statistical significance as in 
the present study.  Most recently, Chaffin et al.
24
 found that IL-6 concentration after exercise was not 
significantly different between phases or the interaction between menstrual phases and exercise time.  
This is the only other study found that looks at IL-6 changes in response to exercise solely in non-
contraceptive using females.  The data from the current study agrees with the findings from previous 
exercise-related research in that although IL-6 concentrations are lower in the luteal phase compared 
to the midfollicular, these differences are not at a level to reach statistical significance. 
Conclusions 
 In conclusion, plasma IL-6 concentration does not appear to be significantly altered across 
the menstrual cycle in response to the fluctuating estradiol levels.  Early studies that were conducted 
in vitro and in animal models found that estrogens attenuate the inflammatory response, as marked by 
lower IL-6 concentrations after treatment with estradiol.
13,15,16 
However, more recent studies exposed 
humans to exercise conditions and while some have approached significance, it has yet to be found 
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that IL-6 concentration varies across the menstrual cycle.
5,8,17,24
 Based on these as well as the current 
findings it cannot be suggested at this time that female athletes should alter their training program 
based on their hormonal status, such as decreasing training levels in the low estrogen, midfollicular 
phase of the menstrual cycle.   
Limitations 
A major limitation to this current study is that it appears underpowered.  The typical accepted 
β level for adequate power is .80, the percent change in IL-6 findings in this study were calculated to 
have a β=.73.  Thus, if statistical significance was to be reached in the study, additional subjects 
would be required.  Regrettably, the recruitment of any additional subjects was restricted by a limited 
pool of eumenorrheic women who met all inclusion criteria. 
Another major limitation to the present study was the technical aspects of performing the IL-
6 assay.  As noted earlier, the investigator had limited practical experience in performing the assay 
and this may have resulted in great “background contamination” in the ELISA results of the assay.  
Additional practicing of the assay would have certainly been beneficial, but the cost of the cytokine 
assay reagents was extremely prohibitive for allowing such practice in the content of this study. 
 
  
   
CHAPTER VI 
Summary, Conclusions, and Recommendations 
Summary 
 Ten active college-aged women who were eumenorrheic and had not used oral contraceptives 
for the previous six months were recruited for this study.  Each subject reported to the laboratory on 
three separate occasions.  On the first visit, subjects completed an incremental exercise test to 
volitional fatigue in order to determine VO2 max and the appropriate experimental workloads.  One of 
the remaining two sessions was conducted during the midfollicular phase of the menstrual cycle when 
estradiol levels are low, and the other session was conducted during the midluteal phase of the 
menstrual cycle, which was characterized by higher estradiol levels.  This natural fluctuation of 
estradiol was used to determine the effect of estrogen on IL-6 concentration in response to exercise.  
These exercise sessions consisted of running at 61% VO2 peak for 60 minutes followed by a 30 
minute recovery period.  Blood draws were taken before the start of exercise, immediately post-
exercise, and 30 minutes into recovery from exercise.  Physiological responses to the 60 minute 
exercise trials (VO2, HR, RPE, and lactate) support that the exercise sessions were similar and did not 
differ from one another in responses. 
 Interleukin-6 concentration was significantly elevated at 30 minutes of recovery after exercise 
from rest levels (main effect time).  However, no significant differences were found for the main 
effect of menstrual cycle phase or the interaction effect between phase and time; although, the main 
effect for menstrual cycle phase approached significance (p=.07; with lower IL-6 observed when 
estradiol was elevated).
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Hypotheses (Accept or Reject) 
Hypothesis 1: Plasma IL-6 concentration will be significantly increased from rest immediately post-
exercise. (Reject) 
Hypothesis 2:  Plasma IL-6 concentration will be significantly increased from rest after 30 minutes of 
recovery from exercise. (Accept) 
Hypothesis 3: Pre-exercise plasma estradiol will be significantly higher during the luteal trials 
compared to follicular trials. (Accept) 
Hypothesis 4:  The %Δ in plasma IL-6 concentration will be significantly lower during luteal trials 
compared to follicular trials from rest to immediately post-exercise. (Reject) 
Hypothesis 5:  The %Δ in plasma IL-6 concentration will be significantly lower during luteal trials 
compared to follicular trials from rest to 30 minutes of recovery. (Reject) 
Future Research 
 Recommendations for future research would be, first to have a larger sample size.  Power 
calculations suggest that additional subjects would be required to find significant differences in IL-6 
across menstrual cycle phase (main effect).  While all subjects are classified as active, exact aspects 
of training programs and regimes was not quantified.  Future research should control for training 
status, as that could have contributed somewhat to the variability in IL-6 concentration.  Another 
methodological factor would be to more closely control diet and the period post-prandial.   
Another area of potential future research could be with respect to how progesterone affects 
inflammation.  Estrogens are not the only fluctuating female hormones and it has been suggested that 
progesterone may play a role in immune function and be a regulator of IL-6 production as well as 
other cytokines.
33,34
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APPENDIX D 
 
LEGEND MAX™ELISA Kit with Pre-coated PlatesBioLegend, 
Inc.biolegend.comSupernatant, Serum, Plasma and Other Biological FluidsELISA Kit for 
Accurate Cytokine Quantitation from Cell Culture 
Cat. No. 
430507 
Human IL-6 
ELISA Kit for Accurate Quantitation of Human IL-6 from Cell Culture Supernatant, Serum, 
Plasma and Other Biological Fluids 
Table of Contents Page  
Introduction…………………………………………………...........................….  
Materials Provided……………………....…………………......................……  
Materials to be Provided by the End-User……………………............…  
Storage Information…………………………………………….......................  
Health Hazard Warnings…………………………………....................………  
Specimen Collection and Handling…………………………….................  
Reagent and Sample Preparation...……………………...................…...  
Assay Procedure…………………………………………………………….............  
Assay Procedure Summary…………………………………………….............  
Calculation of Results…………………………………………………….........….  
Typical Data……………………………………………………………………........….  
Performance Characteristics.........................................................  
Specificity……………………………………………………………..........  
Sensitivity…………………………………………………………........…..  
Recovery……………………………………………………………….........  
Linearity………………………………………………………………..........  
Intra-Assay Precision…………………………………………….........  
Inter-Assay Precision.………………………………………….….…....  
Biological Samples…………………………………………….………....  
Troubleshooting Guide..…………………………………………………….........  
ELISA Plate Template.……….…………………………………………..……......  
 
 
Introduction:  
Human IL-6 (also known as B-cell stimulatory factor 2, Interferon beta-2, Hybridoma growth factor, and CTL 
differentiation factor) plays an essential role in the final differentiation of B-cells into Ig-secreting cells. It 
induces myeloma and plasmacytoma growth, nerve cells differentiation, and acute phase reactants in 
hepatocytes. IL-6 is expressed by T cells, B cells, monocytes, fibroblasts, hepatocytes, endothelial cells, and
 58  
 keratinocytes. It has been shown that IL-6 plays a critical role in many physiological and pathological 
conditions, including autoimmune diseases and rheumatoid arthritis.  
The BioLegend LEGEND MAX™ Human IL-6 ELISA Kit is a Sandwich Enzyme- Linked Immunosorbent Assay 
(ELISA) with a 96-well strip plate that is pre-coated with a capture antibody. This kit is specifically designed for 
the accurate quantitation of human IL-6 from cell culture supernatant, serum, plasma, and other biological 
fluids. This kit is analytically validated with ready-to-use reagents.  
Materials Provided:  
Description  Quantity  
(1 plate)  
Quantity  
(5 plates)  
Volume 
(per bottle)  
Part #  
Anti-Human IL-6 
Pre-coated 96-
well Strip 
Microplate  
1 plate  5 plates  78180  
Human IL-6 
Detection  
Antibody  
1 bottle  5 bottles  12 mL  78181  
Human IL-6 
Standard  
1 vial  5 vials  lyophilized  78182  
Avidin-HRP 
A  
1 bottle  5 bottles  12 mL  79131  
Assay Buffer 
A  
1 bottle  5 bottles  25 mL  78232  
Wash Buffer 
(20X)  
1 bottle  5 bottles  50 mL  78233  
Substrate 
Solution F  
1 bottle  5 bottles  12 mL  79132  
Stop 
Solution  
1 bottle  5 bottles  12 mL  79133  
Plate Sealers  4 sheets  20 sheets  78101 
 
Materials to be Provided by the End-User:  
• Microplate reader able to measure absorbance at 450 nm  
• Adjustable pipettes to measure volumes ranging from 1 μL to 1,000 μL  
• Deionized water  
• Wash bottle or automated microplate washer  
• Log-Log graph paper or software for data analysis  
• Tubes to prepare standard dilutions  
• Timer  
• Plate Shaker  
• Polypropylene vials  
Storage Information:  
Store unopened kit components at 4°C. Do not use this kit beyond its expiration date.  
Opened or Reconstituted Components  
Microplate wells  If not all microplate strips are used, 
remove the excess strips by pressing up 
from underneath each strip. Place 
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excess strips back in the foil pouch with 
the included desiccant pack and reseal. 
Store at 4°C for up to one month.  
Standard  The remaining reconstituted standard 
stock solution can be aliquoted into 
polypropylene vials and stored at -70°C 
for up to one month. Avoid repeated 
freeze-thaw cycles.  
Detection Antibody  Store opened reagents at 4°C and use 
within one month.  
Avidin-HRP A  
Assay Buffer A  
Wash Buffer (20X)  
Substrate Solution F  
Stop Solution  
Health Hazard Warnings:  
1. Reagents that contain preservatives may be harmful if ingested, inhaled or absorbed through the skin. Refer 
to the MSDS online at BioLegend’s website for details (www.biolegend.com/support/#msds).  
2. Substrate Solution F is harmful if inhaled or ingested. Avoid skin, eye and clothing contact.  
3. To reduce the likelihood of blood-borne transmission of infectious agents, 
 
 
handle all serum, plasma and other biological fluids in accordance with NCCLS regulations.  
4. Stop Solution contains 2N sulfuric acid. Wear eye, hand, and face protection.  
5. Before disposing of the plate, rinse it with an excess amount of tap water.  
Specimen Collection and Handling:  
Specimens should be clear and non-hemolyzed. If possible, unknown samples should be run at a number of 
dilutions to determine the optimal dilution factor that will ensure accurate quantitation.  
Cell Culture Supernatant: If necessary, centrifuge all samples to remove debris prior to analysis. It is 
recommended that samples be stored at < -70°C. Avoid repeated freeze-thaw cycles.  
Serum: Use a serum separator tube and allow clotting for at least 30 minutes, then centrifuge for 10 minutes 
at 1,000 x g. Remove serum layer and assay immediately or store serum samples at < -70°C. Avoid repeated 
freeze-thaw cycles.  
Plasma: Collect blood samples in citrate, heparin or EDTA containing tubes. Centrifuge for 10 minutes at 1,000 
x g within 30 minutes of collection. Assay immediately or store plasma samples at < -70°C. Avoid repeated 
freeze-thaw cycles.  
Reagent and Sample Preparation:  
Note: All reagents should be diluted immediately prior to use.  
1. Dilute the 20X Wash Buffer to 1X with deionized water. For example, make 1 liter of 1X Wash Buffer by 
adding 50 mL of 20X Wash Buffer to 950 mL of deionized water. If crystals have formed in the 20X Wash 
Buffer, bring to room temperature and vortex until dissolved.  
2. Reconstitute the lyophilized Human IL-6 Standard by adding the volume of Assay Buffer A indicated on the 
vial label to make the 20 ng/mL standard stock solution. Allow the reconstituted standard to sit at room 
temperature for 15-20 minutes, then briefly vortex to mix completely.  
3. In general, samples are analyzed without dilutions. However, if dilutions are required, use Assay Buffer A as 
the sample diluent.
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Assay Procedure:  
Note: Do not mix reagents from different kits or lots. Reagents and/or antibodies from different 
manufacturers should not be used with this kit.  
1. Bring all reagents to room temperature prior to use. It is strongly recommended that all standards and 
samples be run in duplicate or triplicate. A standard curve is required for each assay.  
2. If not all microplate strips will be used, remove the excess strips by pressing up from underneath each strip. 
Place excess strips back in the foil pouch with the included desiccant pack and reseal.  
3. Prepare 500 μL of the 500 pg/mL top standard by diluting 12.5 μL of the standard stock solution in 487.5 μL 
of Assay Buffer A. Perform six two-fold serial dilutions of the 500 pg/mL top standard in separate tubes 
using Assay Buffer A as the diluent. Thus, the human IL-6 standard concentrations in the tubes are 500 
pg/mL, 250 pg/mL, 125 pg/mL, 62.5 pg/mL, 31.3 pg/ mL, 15.6 pg/mL, and 7.8 pg/mL, respectively. Assay 
Buffer A serves as the zero standard (0 pg/mL). 4. Wash the plate 4 times with at least 300 μL of 1X Wash 
Buffer per well and blot any residual buffer by firmly tapping the plate upside down on absorbent paper. 
All subsequent washes should be performed similarly.  
5. Add 50 μL of Assay Buffer A to each well that will contain either standard dilutions or samples.  
6. Add 50 μL of standard dilutions or samples to the appropriate wells  
7. Seal the plate with a Plate Sealer included in the kit and incubate the plate at room temperature for 2 hours 
while shaking at 200 rpm.  
8. Discard the contents of the plate into a sink, then wash the plate 4 times with 1X Wash Buffer as in step 4.  
9. Add 100 μL of Human IL-6 Detection Antibody solution to each well, seal the plate and incubate at room 
temperature for 1 hour while shaking. 
10. Discard the contents of the plate into a sink, then wash the plate 4 times with 1X Wash Buffer as in step 4.  
11. Add 100 μL of Avidin-HRP A solution to each well, seal the plate and incubate at room temperature for 30 
minutes while shaking.  
12. Discard the contents of the plate into a sink, then wash the plate 5 times with 1X Wash Buffer as in step 4. 
For this final wash, soak wells in 1X Wash Buffer for 30 seconds to 1 minute for each wash. This will help 
minimize background.  
13. Add 100 μL of Substrate Solution F to each well and incubate for 15 minutes in the dark. Wells containing 
human IL-6 should turn blue in color with an intensity proportional to its concentration. It is not necessary 
to seal the plate during this step.  
14. Stop the reaction by adding 100 μL of Stop Solution to each well. The solution color should change from 
blue to yellow.  
15. Read absorbance at 450 nm within 30 minutes. If the reader is capable of reading at 570 nm, the 
absorbance at 570 nm can be subtracted from the absorbance at 450 nm. 
Calculation of Results:  
The data can be best calculated with computer-based curve-fitting software using a 5- or 4-parameter logistics 
curve-fitting algorithm. If an appropriate software is not available, use log-log graph paper to determine 
sample concentrations. Determine the mean absorbance for each set of duplicate or triplicate standards, 
controls, and samples. Plot the standard curve on log-log graph paper with cytokine concentration on the X-
axis and absorbance on the Y-axis. Draw a best fit line through the standard points. To determine the 
unknown cytokine concentrations, find the mean absorbance value of the unknown concentration on the Y-
axis and draw a horizontal line to the standard curve. At the point of intersection, draw a vertical line to the X-
axis and read the cytokine concentration. 
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If samples were diluted, multiply the concentration by the appropriate dilution factor. If a test sample’s 
absorbance value falls outside the linear portion of the standard curve, the test sample needs to be re-
analyzed at a higher (or lower) dilution as appropriate.  
Typical Data:  
This standard curve was generated at BioLegend for demonstration purposes only. A standard curve must be 
run with each assay.  
Performance Characteristics:  
Specificity: No cross-reactivity was observed when this kit was used to analyze the mouse IL-6 and following 
recombinant cytokines/chemokines at up to 50 ng/mL.  
Sensitivity: The minimum detectable concentration of IL-6 is 1.6 pg/mL.  
Recovery: Recombinant IL-6 (250, 125 and 62.5 pg/mL) was spiked into 4 human serum samples, and then 
analyzed with the LEGEND MAXTM Human IL-6 ELISA kit. On average, 96.8 % of the cytokine was recovered 
from serum samples.  
Linearity: Four human serum samples with high concentrations of IL-6 were diluted 1:2, 1:4, 1:8 with Assay 
Buffer A to produce samples with values within the dynamic range and then assayed. On average, 107 % of the 
expected cytokine was detected from serum samples.  
Intra-Assay Statistics: Sixteen replicates of each of two samples containing different IL-6 concentrations were 
tested in one assay.  
Concentration  Sample 1  Sample 2  
Number of 
Replicates  
16  16  
Mean Concentration 
(pg/mL)  
241.8  58.7  
Standard Deviation  10.3  6.7  
% CV  4.3  11.3  
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APPENDIX E 
 
Orientation Session 
Subject ID: __________   Date:__________   Time:_________ 
Height:__________   Weight:____________   Resting 
HR:________ 
Skf Triceps:_____,______,_________     avg:_____ Skf Abd:_____,______,______ avg:_____
  
SKf Suprailium:______,_______,_____ avg:_____ Skf Thigh: _____,______,_____ avg:______ 
Age:___________     Glut Circ:____________ 
Calc %BF:_______________ 
Each stage is 3 minutes long.  Please record average HR for the last 10 seconds of each minute within each 
stage.  During the last 10 seconds for the stage record both HR and RPE.  Regardless of if the stage is complete 
or not, get a final HR and RPE and hit STOP on the timer at the end of the test. 
TREADMILL STAGE 1 
Speed:___1.7____  Minute 1   HR:______ 
    Minute 2   HR:______ 
Grade:___10____  Minute 3   HR:______ RPE:_______ 
TREADMILL STAGE 2 
Speed:___2.5____  Minute 1   HR:______ 
    Minute 2   HR:______ 
Grade:___12____  Minute 3   HR:______ RPE:_______ 
TREADMILL STAGE 3 
Speed:___3.4____  Minute 1   HR:______ 
    Minute 2   HR:______ 
Grade:___14____  Minute 3   HR:______ RPE:_______ 
TREADMILL STAGE 4 
Speed:___4.2____  Minute  1   HR:______ 
    Minute 2   HR:______ 
Grade:___16____  Minute 3   HR:______ RPE:_______ 
TREADMILL STAGE 5 
Speed:___5.0____  Minute  1   HR:______ 
    Minute 2   HR:______ 
Grade:___18____  Minute 3   HR:______ RPE:_______ 
TREADMILL STAGE 6
Speed:___5.5____  Minute  1   HR:______ 
    Minute 2   HR:______ 
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Grade:___20____  Minute 3   HR:______ RPE:_______ 
 
The subject will give a 1 minute warning when the end of the test is nearing.  I will count down that last 
minute.  I will tell the subject to grab the handrails and walk the treadmill to a stop.  Once they grab the 
handrails, hit “STOP” on the treadmill.  When the treadmill stops, the subject will straddle the belt, I’ll remove 
the headgear, and then hit “START” on the treadmill so the subject can cool down.  Subject will walk on the 
treadmill for a few minutes, then be transferred to the table, where they will lie down until HR is below 100.
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APPENDIX F 
Experimental Sessions 
ID:__________  Date:_____ Time:______ Session:_______ Phase:_______ 
Calculated Ex. Intensity:________mL/kg/min Speed:______mph Supine RHR_______bpm 
Exercise Session (HR and RPE Recording) 
Minutes 6-10: VO2 measurement 
10 minutes HR Notes: 
 
 
 RPE 
Minutes 26-30: VO2 measurement 
30 minutes HR Notes: 
RPE 
Minutes 56-60:  VO2 measurement 
60 minutes HR Notes: 
RPE 
 
Plasma Volume Shift Data 
Resting Hct and HB   Immediate Post Hct and Hb Recovery Hct and Hb 
 Hct Hb    Hct Hb   Hct Hb 
Pre 1 ____ ____   Post 1 ____ ____  Rec 1 ____ ____ 
Pre 2 ____ ____   Post 2 ____ ____  Rec 2 ____ ____ 
Pre 3 ____ ____   Post 3 ____ ____  Rec 3 ____ ____
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Avg ____ ____   Avg ____ ____  Avg ____ ____ 
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